SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (456)5/13/1999 10:41:00 PM
From: LLCF  Read Replies (1) | Respond to of 712
 
< Cor's market cap isn't getting any cheaper>

I agree, however these companies are like city hall... takes forever to get anything done. All the "experts" are saying there are going to be all sorts of deals... what is anyone waiting for? These stocks are rallying like nuts!

DAK



To: Edscharp who wrote (456)5/26/1999 1:55:00 PM
From: LLCF  Respond to of 712
 
CNTO' "Fragmin" gets FDA approval for use in patients with unstable angina, a condition marked by severe chest pain, and nonfatal heart attacks called non-Q-wave myocardial infactions.

CORR's market sure is getting crowded isn't it??? CORR still have an edge because their drug is O.K.ed for this and Repro's indication??

DAK


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News